US EditionFosun Pharma Announces 2024 Annual Results
- Fosun Pharma reported operating revenue of RMB41.07 billion and a net profit of RMB2.77 billion for 2024, marking a 16.08% year-on-year increase.
- The company launched seven innovative products and has over 80 projects in its drug pipeline, focusing on R&D expenditures totaling RMB5.55 billion in 2024.
- Fosun Pharma’s innovative anti-PD-1 monoclonal antibody, Han Si Zhuang, is now approved in over 30 countries and benefits more than 100,000 patients worldwide.
- Chairman Wu Yifang stated they aim to lead in healthcare innovation while addressing unmet clinical needs and enhancing global expansion.
Insights by Ground AI
Does this summary seem wrong?
60 Articles
60 Articles
All
Left
4
Center
18
Right
6
Charleston Gazette-Mail+59 Reposted by 59 other sources
Fosun Pharma Announces 2024 Annual Results
Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY
·Charleston, United States
Read Full ArticleCoverage Details
Total News Sources60
Leaning Left4Leaning Right6Center18Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
14%
C 64%
R 21%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
